Start typing to search across the full knowledge system.
Canonical Source · peer reviewed study
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence context
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
Investigation
A separate 2023 AutEMdev feasibility trial involved 66 people with advanced HCC and allowed standard cancer therapy. Independently reviewed tumor responses were available in 37, without a sham/control comparator; these data cannot validate commercial Rife frequency cures.
Subject families